279 related articles for article (PubMed ID: 12707251)
21. Implications of stroke prevention trials: treatment of global risk.
Elkind MS
Neurology; 2005 Jul; 65(1):17-21. PubMed ID: 16009880
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke.
Fletcher GF; Bufalino V; Costa F; Goldstein LB; Jones D; Smaha L; Smith SC; Stone N
Am J Cardiol; 2007 Mar; 99(6C):1E-35E. PubMed ID: 17378996
[No Abstract] [Full Text] [Related]
23. [Hyperlipidemia in patients with ischemic heart disease].
Murase T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():722-7. PubMed ID: 11347161
[No Abstract] [Full Text] [Related]
24. Are we lowering LDL cholesterol sufficiently?
Barter P; Rye KA
Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):290-1. PubMed ID: 16728988
[No Abstract] [Full Text] [Related]
25. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
26. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
27. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL; Topol EJ;
Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
[TBL] [Abstract][Full Text] [Related]
28. Lipid-lowering therapy today: treating the high-risk cardiovascular patient.
Berra K
J Cardiovasc Nurs; 2008; 23(5):414-21. PubMed ID: 18728514
[TBL] [Abstract][Full Text] [Related]
29. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
[TBL] [Abstract][Full Text] [Related]
30. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
[TBL] [Abstract][Full Text] [Related]
31. Discordance between physicians' estimation of patient cardiovascular risk and use of evidence-based medical therapy.
Tsang JL; Mendelsohn A; Tan MK; Hackam DG; Leiter LA; Fitchett D; Lin PJ; Grima E; Langer A; Goodman SG;
Am J Cardiol; 2008 Nov; 102(9):1142-5. PubMed ID: 18940280
[TBL] [Abstract][Full Text] [Related]
32. [Statin cuts cardiovascular risk in half].
Einecke D
MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
[No Abstract] [Full Text] [Related]
33. [Vasoprotective effects of statins and angiotensin II blockers in atherothrombosis].
Egido J; Ruiz-Ortega M; Muñoz-García B; Martín-Ventura JL; Blanco-Colio LM
Nefrologia; 2005; 25 Suppl 2():117-28. PubMed ID: 16050414
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular health. Statin therapy reduces disease in healthy volunteers--but how, exactly?
Couzin J
Science; 2008 Nov; 322(5904):1039. PubMed ID: 19008423
[No Abstract] [Full Text] [Related]
35. Is it time to stop treating dyslipidaemia with fibrates?
Benatar JR; Stewart RA
N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
[TBL] [Abstract][Full Text] [Related]
36. Medical management of abdominal aortic aneurysm.
Golledge J; Powell JT
Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):267-73. PubMed ID: 17540588
[TBL] [Abstract][Full Text] [Related]
37. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
38. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
Lonn E; Grewal J
Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
[TBL] [Abstract][Full Text] [Related]
39. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
[TBL] [Abstract][Full Text] [Related]
40. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
